Although SGLT2 inhibitors caused less HbA1c reduction and, controversially, body weight loss than did GLP-1 agonists, their reduction of blood pressure and heart failure was more significant than those of the GLP-1 agonists. Here, SLC5A2 is linked to heart failure.